Spironolactone for Paroxysmal Atrial Fibrillation

Taichung Veterans General Hospital30 enrolled

Overview

To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.

To determine whether or not adding spironolactone can prevent or delay the occurrence of paroxysmal atrial fibrillation in patients who have received propafenone treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Atrial Fibrillation

Interventions

SpironolactoneDRUG

25 mg po qd 25 mg po bid

PlaceboDRUG

Spironolactone 25 mg po qd

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion criteria: 1. 18 to 80 Y/O, 2. Paroxysmal AF. Exclusion criteria: 1. GPT\>100 IU/L or tota bilirubin \>2 mg/dl; 2. Creatinine \> 2 mg/dl; 3. Serum potassium \>= 5 mM; 4. Serum sodium \<=130 mM; 5. Uric acid \> 10 mg/dl。

Locations (1)

Taichung General Hospital

Taichung, Taiwan

RECRUITING

Outcomes

Primary Outcomes

time to a first electrocardiographically confirmed AF

Time frame: 3 months

Secondary Outcomes

1. Response rate: Improvement of any symptom scores and/or SF36 scores more than 50 % (compared with re-randomization scores) 2. Difference of mean episodes of documented AF between the spironolactone and placebo groups.

Time frame: 3 months

Central Contacts

Tsu-Juey Wu, M.D.

CONTACT

886-4-23592525 tjwu@vghtc.vghtc.gov.tw

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.